Last reviewed · How we verify
Izervay™
Izervay is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage in retinal diseases.
Izervay is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage in retinal diseases. Used for Geographic atrophy secondary to age-related macular degeneration.
At a glance
| Generic name | Izervay™ |
|---|---|
| Also known as | Avacincaptad pegol IVT solution |
| Sponsor | Hoffmann-La Roche |
| Drug class | Complement C3 inhibitor |
| Target | Complement C3 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Izervay (pegcetacoplan) inhibits complement component C3, a key node in the complement cascade that amplifies inflammatory responses. By blocking C3 activation and its downstream effects, the drug reduces complement-mediated inflammation and photoreceptor degeneration in the retina. This mechanism is particularly relevant in age-related macular degeneration (AMD) where complement dysregulation contributes to disease pathology.
Approved indications
- Geographic atrophy secondary to age-related macular degeneration
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Blurred vision
- Injection site reactions
Key clinical trials
- Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) (PHASE2)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE1)
- A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
- ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) (PHASE2)
- Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (PHASE2, PHASE3)
- A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) (PHASE2)
- Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Izervay™ CI brief — competitive landscape report
- Izervay™ updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI